Cargando…
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians’ current knowledge, belief...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574001/ https://www.ncbi.nlm.nih.gov/pubmed/37834994 http://dx.doi.org/10.3390/jcm12196350 |
_version_ | 1785120592319479808 |
---|---|
author | D’Amico, Ferdinando Solitano, Virginia Magro, Fernando Olivera, Pablo A. Halfvarson, Jonas Rubin, David Dignass, Axel Al Awadhi, Sameer Kobayashi, Taku Queiroz, Natália Sousa Freitas Calvo, Marta Kotze, Paulo Gustavo Ghosh, Subrata Peyrin-Biroulet, Laurent Danese, Silvio |
author_facet | D’Amico, Ferdinando Solitano, Virginia Magro, Fernando Olivera, Pablo A. Halfvarson, Jonas Rubin, David Dignass, Axel Al Awadhi, Sameer Kobayashi, Taku Queiroz, Natália Sousa Freitas Calvo, Marta Kotze, Paulo Gustavo Ghosh, Subrata Peyrin-Biroulet, Laurent Danese, Silvio |
author_sort | D’Amico, Ferdinando |
collection | PubMed |
description | As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians’ current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption—whether initiating a biosimilar, transitioning from an originator to a biosimilar, or switching between biosimilars (including multiple switches and reverse switching)—a global survey was conducted. Fifteen physicians with expertise in the field of IBD from 13 countries attended a virtual international consensus meeting to develop practical guidance regarding biosimilar adoption worldwide, considering the survey results. This consensus centered on 10 key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring of biosimilars, non-medical switching, and future perspectives. Ultimately, the consensus affirmed that biosimilars are equally effective and safe when compared to originator drugs. They are considered suitable for both biologic-naïve patients and those who have previously been treated with originator drugs, with cost reduction being the primary motivation for transitioning from an originator drug to a biosimilar. |
format | Online Article Text |
id | pubmed-10574001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105740012023-10-14 Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus D’Amico, Ferdinando Solitano, Virginia Magro, Fernando Olivera, Pablo A. Halfvarson, Jonas Rubin, David Dignass, Axel Al Awadhi, Sameer Kobayashi, Taku Queiroz, Natália Sousa Freitas Calvo, Marta Kotze, Paulo Gustavo Ghosh, Subrata Peyrin-Biroulet, Laurent Danese, Silvio J Clin Med Article As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians’ current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption—whether initiating a biosimilar, transitioning from an originator to a biosimilar, or switching between biosimilars (including multiple switches and reverse switching)—a global survey was conducted. Fifteen physicians with expertise in the field of IBD from 13 countries attended a virtual international consensus meeting to develop practical guidance regarding biosimilar adoption worldwide, considering the survey results. This consensus centered on 10 key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring of biosimilars, non-medical switching, and future perspectives. Ultimately, the consensus affirmed that biosimilars are equally effective and safe when compared to originator drugs. They are considered suitable for both biologic-naïve patients and those who have previously been treated with originator drugs, with cost reduction being the primary motivation for transitioning from an originator drug to a biosimilar. MDPI 2023-10-03 /pmc/articles/PMC10574001/ /pubmed/37834994 http://dx.doi.org/10.3390/jcm12196350 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article D’Amico, Ferdinando Solitano, Virginia Magro, Fernando Olivera, Pablo A. Halfvarson, Jonas Rubin, David Dignass, Axel Al Awadhi, Sameer Kobayashi, Taku Queiroz, Natália Sousa Freitas Calvo, Marta Kotze, Paulo Gustavo Ghosh, Subrata Peyrin-Biroulet, Laurent Danese, Silvio Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus |
title | Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus |
title_full | Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus |
title_fullStr | Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus |
title_full_unstemmed | Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus |
title_short | Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus |
title_sort | practical management of biosimilar use in inflammatory bowel disease (ibd): a global survey and an international delphi consensus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574001/ https://www.ncbi.nlm.nih.gov/pubmed/37834994 http://dx.doi.org/10.3390/jcm12196350 |
work_keys_str_mv | AT damicoferdinando practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT solitanovirginia practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT magrofernando practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT oliverapabloa practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT halfvarsonjonas practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT rubindavid practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT dignassaxel practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT alawadhisameer practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT kobayashitaku practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT queiroznataliasousafreitas practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT calvomarta practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT kotzepaulogustavo practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT ghoshsubrata practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT peyrinbirouletlaurent practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus AT danesesilvio practicalmanagementofbiosimilaruseininflammatoryboweldiseaseibdaglobalsurveyandaninternationaldelphiconsensus |